- Home
- APPF vs ROIV Comparison
APPF vs ROIV Comparison
Compare APPF & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPF
- ROIV
- Stock Information
- Founded
- APPF 2006
- ROIV 2014
- Country
- APPF United States
- ROIV United Kingdom
- Employees
- APPF N/A
- ROIV N/A
- Industry
- APPF Computer Software: Prepackaged Software
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- APPF Technology
- ROIV Health Care
- Exchange
- APPF Nasdaq
- ROIV Nasdaq
- Market Cap
- APPF 7.9B
- ROIV 8.4B
- IPO Year
- APPF 2015
- ROIV N/A
- Fundamental
- Price
- APPF $212.12
- ROIV $10.67
- Analyst Decision
- APPF Buy
- ROIV Buy
- Analyst Count
- APPF 6
- ROIV 4
- Target Price
- APPF $271.20
- ROIV $17.50
- AVG Volume (30 Days)
- APPF 375.8K
- ROIV 5.9M
- Earning Date
- APPF 04-24-2025
- ROIV 05-29-2025
- Dividend Yield
- APPF N/A
- ROIV N/A
- EPS Growth
- APPF 158.56
- ROIV N/A
- EPS
- APPF 5.36
- ROIV N/A
- Revenue
- APPF $824,474,000.00
- ROIV $122,585,000.00
- Revenue This Year
- APPF $20.11
- ROIV N/A
- Revenue Next Year
- APPF $16.68
- ROIV N/A
- P/E Ratio
- APPF $39.61
- ROIV N/A
- Revenue Growth
- APPF 22.73
- ROIV 140.04
- 52 Week Low
- APPF $189.01
- ROIV $8.73
- 52 Week High
- APPF $274.56
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- APPF 47.58
- ROIV 47.82
- Support Level
- APPF $213.49
- ROIV $10.58
- Resistance Level
- APPF $222.34
- ROIV $11.77
- Average True Range (ATR)
- APPF 6.76
- ROIV 0.34
- MACD
- APPF 0.70
- ROIV -0.07
- Stochastic Oscillator
- APPF 68.16
- ROIV 7.56
About APPF AppFolio Inc.
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.